It is with great pleasure to announce and to invite you to join us at The 2nd Asia Pacific Symposium on Diabetes, Hypertension, Metabolic Syndrome and Pregnancy (DIPAP) Greater China to take place this coming October 27 – 28, 2017 in Shanghai, China at the Jing An Shangri La West Shanghai.
The Symposium is held in order to highlight and document scientifically and practically on how to prevent, diagnose and manage HIP to optimize care and outcomes in what is seen as a large knowledge gap within the field. The great success of the previous Ten DIP Symposia held all over Europe and the first in Asia-Pacific in 2016 have paved the way for the Inaugural DIPAP Greater China Symposium. Like the DIP Symposium in Europe, Greater China will aim to raise awareness of the connection between hyperglycemia and poor pregnancy outcomes, where there needs to be a greater global focus on preventing, screening, diagnosing, and managing hyperglycemia in pregnancy.
The DIP Symposium continuously aims to lead a greater global focus on Hypertension in Pregnancy (HIP), maternal and fetal medicine. Doing so by raising awareness of the links between hyperglycemia and poor maternal and fetal outcomes as well as to the future health risks to mother and offspring and demand a clearly defined global health agenda to tackle this issue. To provide guidance for testing, management and care of women with HIP regardless of resource setting as outlined in the FIGO document and to inspire action by showcasing ongoing initiatives on diabetes in pregnancy in the region and globally.
The DIPAP Greater China Symposium will introduce a unique program on “Digital Health” whereby start-up companies, innovative concepts, development of ideas to execution will be brought to the forefront in keynote lectures and demonstrations. A never-before collaboration of Scientific content and hi-tech will meet, listen and discuss on the third day of the Symposium. The Digital Health program will successfully address and highlight the importance of introducing and including digital health within the treatment of Diabetes, Hypertension, Metabolic Syndrome and Pregnancy.
Designated scientific sessions specific to HIP and the specific region is set out to provide in great detail the importance of HIP locally and regionally. It is important for such a course to take place in order to allow participants to receive a great overview of matters concerning their geographical region within a short time frame. The program provides a specific and targeted overview from certain matters of the overall Symposium, allowing it to reach its targeted audience and ideally reach maximum impact in teaching /bringing to light the matters surrounding HIP.
Additionally, controversial topics and use of new technologies in perinatal medicine will be discussed in detail. This will allow participants to formulate a modus operandi through evidence provided by the presenting experts. Innovations connected to perinatal research on Whole Genome Sequencing, NIPT, small RNA’s, Metabolomics and Microbiota will be discussed at length at the Symposium. The faculty comprises of renowned professionals and practitioners from all over the world, who will present the most updated clinical and laboratory revolutions, based on evidence as well as practical experience.
- Luis Cabero Roura, Spain
- Hema Divakar, India (FIGO WG)
- Tony Duan, China
- Moshe Hod, Israel
- Anil Kapur, India
- Ji Linong, China
- Ronald Ma, Hong Kong
- Tahir Mahmood, UK
- Narendra Malhorta, India
- Guang Ning, China
- CN Purandare, India, FIGO President
- Rina Su, China
- Gerard Visser, Netherlands
- Huixia Yang, China (FIGO WG)
- Yariv Yogev, Israel
- Luying Zhang, China
- Non Communicable Disease & Pregnancy global epidemic — It’s all about the mother and the offspring
- Non Communicable Disease & Pregnancy – The FIGO Global vision
- IDF Global Vision: Diabetes in Pregnancy
- Maternal Health – The Impact of Diabetes, Obesity, Hypertension in Pregnancy
- Mother with Pregnancy Induced Complications – How do we Improve Outcome?
- The Fetus — Is There an Optimal Birth Weight?
- The Fetus — Prevention of Preterm Birth: Towards Healthy Mothers and Healthy Babies
- Renovating Maternal Fetal Medicine
- Maternal Fetal Medicine — The Great Obstetrical Syndromes; from basics to molecular biology
- Fetal Medicine — Innovations in prediction and prevention
- New technologies in diabetic pregnancy
- Placental insufficiency: preeclampsia and fetal growth
- Pathogenesis of preeclampsia: Clues to prevention and treatment
- Preeclampsia: identification of pre-clinical disease and management issues
- Early prediction and prevention of IUGR
- IUGR and SGA: Doppler management and prediction of outcomeObesity or Metabolic Syndrome in Pregnancy, which is more hazardous to the mother and offspring?
- Perinatal programming of obesity
- Pre-pregnancy management of the obese patient
- Health system and societal barriers in improving diabetes related maternal health
- Towards a Consensus; The FIGO-GDM Initiative Project
- The Asia Pacific Experience: Learning from the SAIDIP & Greater China experience
- Tribulations and triumphs in implementing a national strategy for GDM screening diagnosis and care in India
- Analysis of the cost-effectiveness of carrying out GDM screening in India
- Gestational diabetes mellitus in China: Difficulties and coping strategies
- Analysis of the cost-effectiveness of carrying out GDM screening in China
- State of the art on insulin analogues and pregnancy
- Differences between early and late onset placental disease — implications for screening
- Aspects of preeclampsia risk calculation: Populations and individuals
- First-trimester maternal risk assessment — A health economic perspective
- Critical evaluation of potential treatments: The case for/against aspirin
- Towards a solution — The ASPRE Study
- Nutritional factors and supplementation on maternal and infant outcome
- Diet and pregnancy outcomes– examples based on the role of micronutrients and macronurients in the development of gestational diabetes
- Nutritional supplementation and the prevention of fetal congenital abnormalitie
- Differences in growth trajectories between infants of women with type-1 and type-2 diabetes?
European Accreditation Council for Continuing Medical Education (UEMS/EACCME)
An application will be made to the European Accreditation Council for Continuing Medical Education (EACCME) for CME accreditation of this event. The EACCME is an institution of the EuropeanUnion of Medical Specialists (UEMS).
American Medical Association (AMA)
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Royal College of Physicians and Surgeons of Canada
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
- Moshe Hod, Israel and Gian Carlo Di Renzo, Italy
- Gian Paolo Donzelli, Italy
- Tony Duan, China
- TY Leung, Hong Kong
- Ji Linong, China, IDF
- Guang Ning, China
- Liona Poon, Hong Kong
- George SH Yeo, Singapore